Alirocumab
Nephrotic Syndrome
Gloria Vegamonoclonal_antibodyPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Nephrotic Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CYCLOSPORIN A Alexandria University | Phase 4 | B |
nc-503 Bellus Health Inc. - a GSK company | Phase 2/3 | B |
FUROSEMIDE University Hospital Tuebingen | Phase 3 | B |
Amiloride University Hospital Tuebingen | Phase 3 | B |
DEXAMETHASONE National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 2 | B |
Lipitor Gloria Vega | Phase 2 | CCC |
PRAVASTATIN University of North Carolina, Chapel Hill | Phase 1 | CC |
Same molecule, other indications
Alirocumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →